Research Efforts Fuel the Future of Global Obstructive Lung Disease Management

出版日期: | 出版商: Frost & Sullivan | 英文 80 Pages | 商品交期: 最快1-2個工作天內

  • 全貌
  • 簡介
  • 目錄

由於各種因素,包括環境因素,呼吸系統疾病在全球範圍內正在增加。慢性阻塞性肺病 (COPD)、哮喘和囊性纖維化等阻塞性肺病是全球醫療系統的主要負擔。現有的治療方法只能減輕影響並提供短期緩解,但不能完全治癒肺部疾病。吸入性皮質類固醇被廣泛用於治療 COPD 和哮喘,但它們對患者有長期的副作用。此外,諸如用於治療 COPD 的肺移植和為治療 COPD 和中度至重度哮喘而開發的含有單克隆抗體的生物製劑等治療方法對於大多數患者來說既昂貴又方便。

在如何使用呼吸藥物方面也存在一些問題。在口服吸入的情況下,存在藥物沉積的問題,根據給藥方法,肺的分子減少,藥物在靶點的功效和生物利用度降低。基因療法等療法正在試驗超越病毒載體遞送的新方法,例如基於脂質的遞送。通過用脂質包被 CFTR 基因直接遞送可防止顆粒降解並實現靶向遞送。



第 1 章戰略主張

  • 為什麼增長變得越來越困難?戰略主張:對增長造成壓力的因素
  • 戰略主張
  • 阻塞性肺病管理行業三大戰略命題的影響
  • 增長機會加速增長管道引擎 (TM)

第 2 章調查背景及調查結果總結

  • 調查背景
  • 調查範圍和重要問題
  • 調查方法
  • 阻塞性肺疾病管理情況的主要發現
  • COVID-19 患者的風險增加

第 3 章阻塞性肺病管理—當前的治療和挑戰

  • 阻塞性肺病管理的醫療需求未得到滿足
  • COPD 現有治療方法面臨的挑戰
  • 現有治療哮喘和囊性纖維化的挑戰
  • 解決問題的新舉措
  • 應對挑戰的治療

第 4 章阻塞性肺疾病的管理-發育中治療

  • 生物製藥
  • 生物製藥-主要發展
  • 小分子
  • 小分子-主要發展
  • 基因治療
  • 基因治療-主要發展
  • RNA療法
  • RNA 療法-主要發展
  • 幹細胞療法
  • 幹細胞療法-主要發展
  • 聯合療法
  • 聯合療法-主要發展
  • 臨床試驗和按方式分類
  • 技術採用和對研究的影響

第 5 章阻塞性肺疾病的管理——設計新的輸送系統

  • 靶向和穩定性藥物遞送系統的進展
  • 靶向遞送系統的新方法
  • 基於納米顆粒的遞送系統的類型

第 6 章阻塞性肺病管理-知識產權、商業化、融資和區域趨勢

  • 阻塞性肺病管理專利情況
  • 專利模式分類
  • 患者技術篩選方面的頂級專利

第 7 章未來呼吸系統疾病的管理

  • 越來越多地採用數字和智能技術
  • 使用智能吸入器克服依從性挑戰
  • 主要進展和參與者
  • 協作以採用智能技術

第 8 章主要公司

  • NuvoAir
  • Adherium
  • OmniSpirant
  • Synairgen
  • Eloxx Pharmaceuticals
  • Regeneron Pharmaceuticals

第 9 章總體增長機會

  • 增長機會 1:開發適合全球採用智能技術的環境
  • 增長機會 2:加強初創企業與主要製藥公司之間的合作,以開發 RNA 療法
  • 增長機會 3:通過合作改進交付策略和處方

第 10 章附錄

  • 哮喘:III 期臨床試驗
  • 囊性纖維化:III 期臨床試驗
  • COPD:III期臨床試驗

第 11 章主要行業影響

  • 行業互動

第 12 章後續步驟

  • 下一步
  • 為什麼是 Frost,為什麼是現在?
  • 免責聲明
Product Code: D9FC

Technology Developments Driving Transformational Growth in Treatment Modalities for Obstructive Lung Diseases

Respiratory diseases are on the rise globally due to various factors, including environmental ones. Obstructive lung diseases such as chronic obstructive pulmonary disease (COPD), asthma, and cystic fibrosis are a huge burden on the global healthcare system. Existing therapies can only reduce the impact and provide short-term relief, but are not capable of curing lung diseases. Inhaled corticosteroids are widely used in the treatment of COPD and asthma, but they leave long-term side effects on patients. Treatment options such as lung transplants to treat COPD and biologics, which include monoclonal antibodies developed to treat COPD and moderate to severe asthma, are expensive and inaccessible to most patients.

The administration mode of respiratory drugs also has several challenges. Oral inhalation can result in drug deposition issues where molecules in the lungs are decreased due to the administration mode, reducing the drug's efficacy and bioavailability at the site of interest. For therapies such as gene therapies, newer approaches that go beyond viral vector deliveries such as lipid-based deliveries are being tested. The cystic fibrosis transmembrane conductance regulator (CFTR) gene can be directly delivered with lipid molecule coating to overcome particle degradation and increase target specific delivery.

In this report, Frost & Sullivan provides a glimpse into the near future of respiratory disease treatment by highlighting newer therapeutics and advanced technologies that can address existing challenges in obstructive lung disease management. Frost & Sullivan has identified new therapies across six areas of high interest and growth: small molecules, biologics, gene therapy, stem cell therapy, ribonucleic acid (RNA) therapy, and combination therapies. Poor patient adherence and the lack of continuous tracking systems to monitor improvements have resulted in low outcomes. Along with newer therapeutics, advanced technologies, such as smart inhalers, and the use of digital therapeutics can enhance self-management and reduce hospitalization.

The study also covers opportunities led by big pharmaceutical and medical devices companies and new collaborations in developing affordable and quality-driven treatments. Cost-effective smart technologies can help in monitoring patients, taking preventive measures, and alerting patients to possible unexpected asthma or COPD attacks. Although most of these newer therapeutics are still in the pre-clinical stage, the results have been promising and show high potential to control and cure obstructive lung diseases.

Key questions addressed:

  • What are the current methods of treatment and their challenges?
  • What are the new trends and their clinical status?
  • What is the patent filing trend?
  • What are the recent research and development activities and collaborations?
  • What are the key companies in action?
  • What are the growth opportunities for companies developing new therapeutics and technologies for obstructive lung disease management?

Table of Contents

1.0 Strategic Imperatives

  • 1.1 Why Is It Increasingly Difficult to Grow?The Strategic Imperative 8™: Factors Creating Pressure on Growth
  • 1.2 The Strategic Imperative 8™
  • 1.3 The Impact of the Top Three Strategic Imperatives in theObstructive Lung Disease Management Industry
  • 1.4 Growth Opportunities Fuel the Growth Pipeline Engine™

2.0 Research Context and Summary of Findings

  • 2.1 Research Context
  • 2.1 Research Context (continued)
  • 2.2 Research Coverage and Key Questions
  • 2.3 Research Methodology
  • 2.4 Key Findings in the Obstructive Lung Disease Management Landscape
  • 2.5 Increased Risks in COVID-19 Patients

3.0 Obstructive Lung Disease Management-Current Therapies and Challenges

  • 3.1 Unmet Medical Needs for Obstructive Lung Disease Management
  • 3.2 Challenges in Existing Therapeutics for COPD
  • 3.3 Challenges in Existing Therapeutics for Asthma and Cystic Fibrosis
  • 3.4 New Efforts to Address Challenges
  • 3.5 Therapies to Address Challenges

4.0 Obstructive Lung Disease Management-Therapeutics in Development

  • 4.1 Biologics
  • 4.1.1 Biologics-Key Developments
  • 4.2 Small Molecules
  • 4.2.1 Small Molecules-Key Developments
  • 4.3 Gene Therapy
  • 4.3.1 Gene Therapy-Key Developments
  • 4.4 RNA Therapy
  • 4.4.1 RNA Therapy-Key Developments
  • 4.5 Stem Cell Therapy
  • 4.5.1 Stem Cell Therapy-Key Developments
  • 4.6 Combination Therapy
  • 4.6.1 Combination Therapy-Key Developments
  • 4.7 Clinical Trials and Classification by Modality
  • 4.8 Technology Adoption and Research Impact
  • 4.8 Technology Adoption and Research Impact (continued)

5.0 Obstructive Lung Disease Management-Designing New Delivery Systems

  • 5.1 Advancements in Drug Delivery Systems for Targeting and Stability
  • 5.2 New Approaches in Targeted Delivery Systems
  • 5.3 Types of Nanoparticle-based Delivery Systems

6.0 Obstructive Lung Disease Management-IP, Commercialization, Funding, and Regional Trends

  • 6.1 Patent Landscape for Obstructive Lung Disease Management
  • 6.2 Patent Classification by Modality
  • 6.3 Top Patents in Screening Patients Technology
  • 6.3 Top Patents in Screening Patients Technology (continued)

7.0 Future Management of Respiratory Diseases

  • 7.1 Increased Adoption of Digital and Smart Technologies
  • 7.2 Overcoming Adherence Challenges with Smart Inhalers
  • 7.3 Key Developments and Participants
  • 7.4 Collaborations for Smart Technologies Adoption

8.0 Key Companies

  • 8.1 NuvoAir
  • 8.2 Adherium
  • 8.3 OmniSpirant
  • 8.4 Synairgen
  • 8.5 Eloxx Pharmaceuticals
  • 8.6 Regeneron Pharmaceuticals

9.0 Growth Opportunity Universe

  • 9.1 Growth Opportunity 1: Developing a Suitable Environment for Global Adoption of Smart Technologies
  • 9.1 Growth Opportunity 1: Developing a Suitable Environment for Global Adoption of Smart Technologies (continued)
  • 9.2 Growth Opportunity 2: Increasing Collaborations Between Start-Ups and Big Pharma Companies to Develop RNA Therapeutics
  • 9.2 Growth Opportunity 2: Increasing Collaborations Between Start-Ups and Big Pharma Companies to Develop RNA Therapeutics (continued)
  • 9.3 Growth Opportunity 3: Improving Delivery Strategies and Formulations through Partnerships
  • 9.3 Growth Opportunity 3: Improving Delivery Strategies and Formulations through Partnerships (continued)

10.0 Appendix

  • 10.1 Asthma-Phase III Clinical Trials
  • 10.1 Asthma-Phase III Clinical Trials (continued)
  • 10.1 Asthma-Phase III Clinical Trials (continued)
  • 10.2 Cystic Fibrosis-Phase III Clinical Trials
  • 10.3 COPD-Phase III Clinical Trials

11.0 Key Industry Influencers

  • 11.1 Industry Interactions
  • 11.1 Industry Interactions (continued)

12.0 Next Steps

  • 12.1 Your Next Steps
  • 12.2 Why Frost, Why Now?
  • Legal Disclaimer